Johnson & Johnson orthopedic sales up 1.2% in Q3: 5 things to know

Johnson & Jonson reported its orthopedics line had a 1.2 percent increase in sales for the third quarter.

Advertisement

Five things to know:

1. Worldwide orthopedics sales hit $2.1 billion, a 1.2 percent increase compared to the same period last year. Both U.S. and international sales were up 1.2 percent, to $1.3 billion and $837 million, respectively.

2. U.S. knee sales were down 2.7 percent to $209 million, but international sales jumped nearly 8 percent to $136 million. Overall knee sales for the quarter were $344 million, a 1.2 percent increase.

3. Spine and other sales were down nearly 1 percent worldwide to $778 million. In the U.S., spine and other sales were relatively flat at $472 million, but international sales were down 2 percent to $306 million.

4. Hip sales in the U.S. were up 1.1 percent to $204 million while international sales were up 2.7 percent to $133 million. Overall hip sales increased 1.7 percent to $336 million.

5. Trauma sales in the U.S. were up 5.1 percent to $415 million while international sales were up 1 percent to $262 million. Overall trauma sales increased 3.5 percent to $677 million.

More articles on orthopedic devices:
15 hospitals installing robots for spine, orthopedics in 2019
Excelsior Orthopaedics merger complete, brings group to 90 providers
145 orthopedic surgeon moves in 2019 through Q3

At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.

Register to Attend Webinar

160 ambulatory leaders just ranked the EHR as the single system most overdue for AI reinvention

Tuesday, August 11
12:00 PM - 1:00 PM CDT

Presenter: Gautam Shah, MBA, FACHDM, NextGen Healthcare

Advertisement

Next Up in Spinal Tech

Advertisement

Comments are closed.